Loading...
Loading...
NEXI| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.4M |
| Gross Profit | -0.4M |
| Operating Expense | 9.8M |
| Operating I/L | -9.8M |
| Other Income/Expense | 0.1M |
| Interest Income | 0.3M |
| Pretax | -9.6M |
| Income Tax Expense | -260.3M |
| Net Income/Loss | 250.8M |
NexImmune, Inc. is a clinical-stage biotechnology company specializing in developing T cell immunotherapies for cancer and immune-mediated diseases. The company's proprietary Artificial Immune Modulation nanoparticle technology platform is the foundation for its product candidates, including NEXI-001, an allogeneic cell therapy for acute myeloid leukemia, NEXI-002, an autologous cell therapy for multiple myeloma, and NEXI-003, a candidate targeted against HPV-associated malignancies. These therapies are in various stages of clinical development, with the potential to address unmet medical needs and generate revenue through successful commercialization.
